Oncternal Therapeutics Inc Value Stock - Dividend - Research Selection
Gtx inc
ISIN: US68236P1075 , WKN: A2PL3P
Market price date:
Market price:
Market price:
Fundamental data and company key figures of the share
| Annual reports in | |||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Key figures | |||||||||||||||||||||||||||||||||||||||||||||||||
| Cash flow | |||||||||||||||||||||||||||||||||||||||||||||||||
| Net operating cash flow | |||||||||||||||||||||||||||||||||||||||||||||||||
| Capital Expenditures | |||||||||||||||||||||||||||||||||||||||||||||||||
| Free cash flow | |||||||||||||||||||||||||||||||||||||||||||||||||
| Balance sheet | |||||||||||||||||||||||||||||||||||||||||||||||||
| Total Equity | |||||||||||||||||||||||||||||||||||||||||||||||||
| Liabilities & Shareholders equity | |||||||||||||||||||||||||||||||||||||||||||||||||
| Income statement | |||||||||||||||||||||||||||||||||||||||||||||||||
| Net income | |||||||||||||||||||||||||||||||||||||||||||||||||
| Eps (diluted) | |||||||||||||||||||||||||||||||||||||||||||||||||
| Diluted shares outstanding | |||||||||||||||||||||||||||||||||||||||||||||||||
| Net sales/revenue | |||||||||||||||||||||||||||||||||||||||||||||||||
Do you want to do make a detailed fundamental analysis of this stock?
✓ NEW Fundamental API Access to 500 data points per month
✓ Fundamental data up to 25 years
✓ Comparison to all other stocks by the FScore
✓ Time saving!
✓ NEW Fundamental API Access to 500 data points per month
✓ Fundamental data up to 25 years
✓ Comparison to all other stocks by the FScore
✓ Time saving!
How our site works ...
✓ Non-binding 7 days without automatic subscription
✓ No termination required after the free week
✓ Finanzoo fundamental analysis
✓ Data updated daily
✓ Virtual depots
✓ Share alarms via email
✓ Subscription can be canceled at any time at the end of the month
✓ Choice of desired shares
✓ Over 2000 stock analyzes available
✓ Bitcoin payment possible if you do not want to subscribe
Price for monthly subscription $ 19.99 / month including VAT.
| Description | Data |
|---|---|
| Symbol | |
| Market Capitalization | USD |
| Country | |
| Indices | |
| Sectors | |
| Raw Data Source | |
| Stock Split | |
| Internet |
Description of the company
GTx, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of medicines for the treatment of stress urinary incontinence (SUI) and prostate cancer. It focuses on the development of selective androgen receptor modulators (SARMs) for the treatment of breast cancer, SUI, and Duchenne muscular dystrophy; and selective androgen receptor degraders to treat progressive castration-resistant prostate cancer. The company\'s lead SARM candidate is the enobosarm GTx-024, a Phase II open-label proof-of-concept clinical trial for patients with androgen receptor (AR) positive triple-negative breast cancer; and estrogen receptor positive and AR positive advanced breast cancer, as well as postmenopausal women with SUI. GTx, Inc. was founded in 1997 and is headquartered in Memphis, Tennessee.
The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,
NEWS
Analysts Offer Insights on Healthcare Companies: Oncternal Therapeutics (ONCT) and Viracta Therapeutics (VIRX)
2023-03-14
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.
Oncternal Therapeutics, Inc. (NASDAQ:ONCT) Q4 2022 Earnings Call Transcript
2023-03-11
Oncternal Therapeutics, Inc. (NASDAQ:ONCT) Q4 2022 Earnings Call Transcript March 9, 2023 Operator: Greetings and welcome to the Oncternal Therapeutics, Inc. Fourth Quarter 2022 Financial Results Conference Call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. And as a reminder, this conference is being […]
Analysts Are Bullish on Top Healthcare Stocks: Oncternal Therapeutics (ONCT), Helius Medical Technologies (HSDT)
2023-03-11
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.
Oncternal Therapeutics, Inc. (ONCT) Q4 2022 Earnings Call Transcript
2023-03-09
Oncternal Therapeutics, Inc. (NASDAQ:NASDAQ:ONCT) Q4 2022 Earnings Conference Call March 9, 2023 5:00 PM ETCompany ParticipantsJames Breitmeyer - President and CEORichard Vincent - CFOSalim...
Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2022 Financial Results
2023-03-09
Encouraging and improving interim Phase 1/2 study results for zilovertamab plus ibrutinib in patients with MCL and CLL, including those with mutated TP53 and/or del(17p), presented at ASH in December 2022Zilovertamab global Phase 3 registrational Study ZILO-301 for the treatment of patients with MCL initiatedPhase 1/2 study for ONCT-808, our autologous CAR-T program targeting ROR1-expressing hematologic malignancies, initiated with initial clinical data expected in late 2023Helpful FDA pre-IND c
Oncternal Therapeutics: Q4 Earnings Snapshot
2023-03-09
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.
Oncternal Therapeutics GAAP EPS of -$0.20 beats by $0.01, revenue of $0.17M misses by $0.11M
2023-03-09
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.
Notable earnings after Thursday`s close
2023-03-08
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.
Oncternal Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2022 Financial Results
2023-03-02
SAN DIEGO, March 02, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report fourth quarter and full year 2022 financial results after the U.S. financial markets close on Thursday, March 9, 2023. Oncternal’s management will host a webcast at 2:00 p.m. PT (5:00 p.m. ET) to provide a comprehensive business update and discuss the Company’s financial re
Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
2023-03-01
SAN DIEGO, March 01, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it has granted an inducement award to one new employee, Yelena Tsabur, who joined Oncternal as Associate Clinical Trial Manager. The award was made on March 1, 2023 under Oncternal’s 2021 Employment Inducement Incentive Award Plan, which provides for the granting of equity awards to new e